ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novartis hits targets in late-stage QMF149 asthma trial pharmatimes
June 05, 2019Novartis has announced that a phase III QUARTZ study of its investigational inhaled combination treatment, QMF149, has met primary and key secondary endpoints in patients with inadequately controlled asthma.
Pharma Sources Insight January 2025
